Scientific Director
Leader of a research team within a hybrid academic lab/start-up company of 200+ individuals striving to cure heritable disease with recombinant adeno-associated virus (rAAV) harboring therapeutic transgenes. Aimed to improve the durability of therapeutic transgene expression, with an end goal of sustained expression over a patient’s lifetime.• Designed and developed programmable DNA processing of rAAV genomes in vivo:• Engineered human DNA sequences to replace field’s reliance on viral gene promoters susceptible to chromatin-mediated transcriptional silencing• Recruited and mentored team members for individual and group success• Interacted with sponsors to update progress, promise and challenges